Taro Pharmaceutical Industries Ltd (TARO.N)
|Market Cap (Mil.):||$4,964.75|
|Shares Outstanding (Mil.):||44.79|
MUMBAI - Sun Pharmaceutical Industries Ltd, India's biggest drugmaker by market value, is looking for partnerships or acquisitions to enter Japan, an especially lucrative market for manufacturers of low-cost drugs, a senior executive said.
Reuters Market Eye - Sun Pharmaceutical Industries gains 1 percent after unit Taro Pharmaceutical Industries announced the start of a tender offer to buy back up to $200 million of its ordinary shares.
* India's Sun Pharmaceutical Industries Ltd gains 1 percent after unit Taro Pharmaceutical Industries announced the start of a tender offer to buy back up to $200 million of its ordinary shares. * If the offer is fully subscribed, the number of Taro shares to be purchased in the offer represents approximately 4.6 to 5.3 percent of the unit's total outstanding shares. * Sun Pharma's stake in Taro will go up to more than 69 percent from 66 percent should the buyback be fully subscribed. (abhi
BRIEF-Bluemountain Capital Management and Iszo Capital file lawsuit against Taro Pharmaceutical Industries
Nov 21 - BlueMountain Capital Management: * Bluemountain Capital Management and Iszo Capital file lawsuit against Taro
Reuters Markete Eye - Sun Pharmaceutical Industries Ltd gains 2.8 percent after its unit Taro Pharmaceutical Industries Ltd operational earnings beat some analysts estimates.
* India's Sun Pharmaceutical Industries Ltd gains 3 percent after its unit Taro Pharmaceutical Industries Ltd operational earnings beat some analysts estimates. * Taro's quarterly earnings per share came at $2.15 while sales rose 27.5 percent to $205.3 million. * Analysts say a price hike in certain product categories by Taro led to the operating earnings beat while also boosting outlook for Sun Pharmaceutical's earnings results later in the day. (email@example.com /; abhis
* Shares in India's Sun Pharmaceutical Industries Ltd fall 1 percent as the U.S. Food and Drug Administration approval for Glenmark's Desoximetasone ointment is seen negative for the former's unit, Taro Pharmaceutical Industries Ltd. * Analysts tracking the sector say the leading brand in this segment is Taro's Topicort, which had annual sales of $50 million. * Also, Citigroup in a report says while Taro has also lost market share in its largest product Nystatin/Triam combo, it could see more
|Ranbaxy Laboratories Limited (RANB.NS)||Rs364.10||-0.50|
|Pfizer Inc. (PFE.N)||$32.42||+0.03|
|Novartis AG (NOVN.VX)||CHF72.90||+0.30|
|Merck & Co., Inc. (MRK.N)||$56.69||-0.63|
|Bayer AG (BAYGn.DE)||€95.63||-0.81|
|Bayer AG (BAYE.F)||--||--|
|GlaxoSmithKline plc (GSK.L)||1,674.00p||+1.50|
|Eli Lilly & Co. (LLY.N)||$58.43||-0.47|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||17,200.00₪||-10.00|
|Bristol-Myers Squibb Co (BMY.N)||$55.83||-0.31|